Prescription drug · ANDA
Fenofibrate NDC 68788-4006
Fenofibrate 145 mg/1 · Tablet · Oral · Preferred Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68788-4006-1 | 68788400601 | 100 TABLET in 1 BOTTLE (68788-4006-1)Marketed from Aug 8, 2025 | |
| 68788-4006-3 | 68788400603 | 30 TABLET in 1 BOTTLE (68788-4006-3)Marketed from Aug 8, 2025 | |
| 68788-4006-6 | 68788400606 | 60 TABLET in 1 BOTTLE (68788-4006-6)Marketed from Aug 8, 2025 | |
| 68788-4006-9 | 68788400609 | 90 TABLET in 1 BOTTLE (68788-4006-9)Marketed from Aug 8, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fenofibrate
- Generic name (nonproprietary)
- fenofibrate
- Active ingredients
- Fenofibrate — 145 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 090856
- Marketing start
- Listing expires
- Identifiers
- Product ID 68788-4006_2e6711e9-782d-46bd-9447-6612fe7d0fe7SPL ID 2e6711e9-782d-46bd-9447-6612fe7d0fe7SPL set ID 2e6711e9-782d-46bd-9447-6612fe7d0fe7RxCUI 477560UNII U202363UOS
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468788400601followed by a unit qualifier and the quantityPackage 68788-4006-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: • To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). • For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets USP are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholest…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 090856
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fenofibrate | Fenofibrate 145 mg/1 | TabletOral | Northwind Health Company, LLC | 82868-018 |
| Fenofibrate | Fenofibrate 48 mg/1 | TabletOral | American Health Packaging | 60687-618 |
| Fenofibrate | Fenofibrate 145 mg/1 | TabletOral | American Health Packaging | 60687-629 |
| Fenofibrate | Fenofibrate 145 mg/1 | TabletOral | Major Pharmaceuticals | 0904-7480 |
| Fenofibrate | Fenofibrate 48 mg/1 | TabletOral | Lupin Pharmaceuticals, Inc. | 68180-388 |
| Fenofibrate | Fenofibrate 145 mg/1 | TabletOral | Lupin Pharmaceuticals, Inc. | 68180-389 |
| Fenofibrate | Fenofibrate 48 mg/1 | TabletOral | AvPAK | 50268-338 |